ArticleBMC ophthalmology2026
Pars planitis: a study of clinical features and treatment results.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to report the clinical findings, treatment modalities, and success rates of pediatric cases with pars planitis followed up in our clinic. MATERIALS AND
methodsThis retrospective and cohort study included 46 eyes of 23 patients followed up with a diagnosis of pars planitis. Patients’ age, gender, age at symptom onset, follow-up period, initial and final visual acuity (VA) according to Snellen chart, angiographic findings and scores, initial immunosuppressive treatment, developing anterior and posterior segment complications, need for surgery, reason for and age at initiation of biological agents, side effects due to medications were recorded.
results15 of the patients were male and 8 were female, and the average age was 13.26 ± 3.18 (8–17) years. The average follow-up period was 38.09 ± 19.52 (6–72) months. According to the Snellen chart, initial and final best-corrected VA values were 0.6 ± 0.3 and 0.8 ± 0.2, respectively, and they increased statistically significantly (p < 0.001). Fundus fluorescein angiography (FA) performed at the time of diagnosis revealed optic disc staining in all eyes and vascular leakage in 42 eyes. The FA score at the time of the initial visit was 17.09 ± 7.21, while the FA score at the last visit was 8.52 ± 6.9 (p < 0.001). Macular edema was detected in 10 eyes, retinoschisis was detected in 6 eyes, and papillitis was detected in 15 eyes. The preferred initial treatment was methotrexate in 17 patients, azathioprine in 4 patients, and methotrexate and adalimumab in 2 patients. During follow-up, biological agents were started in 20 of 23 patients.
conclusionPars planitis is a resistant and severe uveitis entity in children. With early diagnosis and early initiation of non-corticosteroid treatment, ocular complications that may develop can be prevented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.